Загрузка...
Safety of lorlatinib following alectinib-induced pneumonitis in two patients with ALK-rearranged non-small cell lung cancer: a case series
Drug-induced interstitial lung disease (DI-ILD) is a rare adverse event associated with targeted therapies that inhibit the anaplastic lymphoma kinase (ALK) protein. Although newer-generation ALK inhibitors such as alectinib significantly improve survival in metastatic ALK-rearranged non-small cell...
Сохранить в:
| Опубликовано в: : | Transl Lung Cancer Res |
|---|---|
| Главные авторы: | , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
AME Publishing Company
2021
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7867755/ https://ncbi.nlm.nih.gov/pubmed/33569330 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21037/tlcr-20-564 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|